-
Featured
Mortality in COVID-19 Does Not Appear to Be Driven by Liver Failure
Massachusetts General Hospital researchers report that elevated liver function tests are common in COVID-19, but severe liver injury is rare, and no case of liver failure or dysfunction leading to death has been attributed directly to COVID-19.
-
Featured
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Featured
Early Transplantation for Alcohol-associated Hepatitis Improves Survival
According to a mathematical model, offering liver transplantation with no minimum period of sobriety before surgery (i.e., early liver transplantation) for severe alcohol-associated hepatitis provides a fourfold increase in life expectancy compared with requiring a six-month period of sobriety before listing. having characteristics similar to patients in ACCELERATE-AH trial.
-
Case Series: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
Ryan J. Sullivan, MD, Michael L. Dougan, MD, PhD, and colleagues have reported the first three cases of using a Janus kinase (JAK) inhibitor to treat hepatitis associated with immune checkpoint inhibitor therapy. All patients showed excellent response to tofacitinib, although their oncologic outcomes varied.
-
Healthcare–related Transportation Insecurity Is a Critical Social Risk Factor in Chronic Liver Disease
Nneka N. Ufere, MD, MSCE, Marina Serper, MD, MS, and colleagues found using nationwide U.S. data that 6% of patients with chronic liver disease report healthcare–related transportation insecurity, which about doubled the risk of mortality even after adjustment for income and other social risk factors.
-
Review: The Evolving Role of Quantitative Ultrasound for Fatty Liver Disease
Arinc Ozturk, MD, Anthony E. Samir, MD, MPH, and colleagues say advances in ultrasound hardware, signal processing, computational efficiency, and analytic algorithm development have led to exciting new quantitative tools that promise to increase the reliability of diagnosing hepatic steatosis.
Liver Contributors
-
Emily D. Bethea, MD
Associate Clinical Director of Liver Transplantation, Massachusetts General Hospital
-
Jagpreet Chhatwal, PhD
Associate Director, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
Recent Article
County-level COVID-19 Data Confirms Effectiveness of Workplace Closure
-
Kathleen E. Corey, MD, MPH, MMSc
Director, Fatty Liver Clinic, Mass General Gastrointestinal Unit, Associate Professor of Medicine, Harvard Medical School
Recent Article
Tobacco Use and Type 2 Diabetes Have Additive Effect on Risk of Fibrosis in Patients With MASLD
-
Raymond T. Chung, MD
Vice Chief, Division of Gastroenterology, Director, Hepatology and Liver Center, Massachusetts General Hospital
Recent Article
Monitoring Novel HBV Markers Worthwhile in HBeAg-positive Patients Coinfected With HIV
-
Russell P. Goodman, MD, DPhil
Hepatologist, Division of Gastroenterology, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Imbalance of Electrons in the Liver May Be A Risk Factor for Many Common Diseases
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.